TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05316090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: Neurodevelopmental training excercises
Study: NCT04803968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bicycle ergometer and arm ergometer exercise
Description: After the bicycle ergometer training is completed, there will be a 15-minute break for blood pressure measurement of the patients.~Then the combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.~For this, the patient will sit upright in front of the height-adjustable arm ergometer stand (Lode Angio Arm Ergometer with Automat) with the fulcrum of the handle at shoulder height.~The arm endurance training group will work for a total of 20 minutes, at 60% of the peak workload and at 50 rpm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bicycle ergometer exercise
Description: All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training (Lode Corival Cpet Ergoline type: 960900 serial number: 20160094, Netherlands). The exercise protocol for the lower extremities will consist of a total of 40 minutes, including an 8-minute warm-up phase and an 8-minute cool-down phase. Exercise intensity, on the other hand, will be arranged as recommended in the European Society of Cardiology (ESC) 2020 guideline for chronic heart failure patients, at a workload corresponding to 70-80% of peak oxygen consumption (VO2peak), with a turnover rate of 60 cycles / min.
Study: NCT04711876

Intervention type: BIOLOGICAL
Intervention: Cytokine level in blood and CSF
Description: Measure of cytokine level

Intervention type: BIOLOGICAL
Intervention: Cytokine level in blood and CSF
Description: Measure of cytokine level
Study: NCT06379802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized physical activity and diet
Description: Precision health
Study: NCT05338281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
Study: NCT06049290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-034 for Injection
Description: Initial dose - MTD; Q2W; intravenous infusion
Study: NCT05662306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil
Description: 1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
Study: NCT03969199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
Study: NCT05541848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical supervised exercises with laser-guided feedback (ELGF)
Description: Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes.
Study: NCT05043259

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: inactive SARS-CoV-2 vaccine (Vero cell)
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose aerosolized Ad5-nCoV
Description: This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose aerosolized Ad5-nCoV
Description: This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
Study: NCT05604937

Intervention type: OTHER
Group type: OTHER
Intervention: Shi's traumatology osteopathic manipulation
Description: Patients receive treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments. The manipulation intervention has mainly two steps: First, doctors perform soft-tissue manipulation on neck and shoulders to relax for 10 min; Second, doctors perform manipulation to reconstruct atlantoaxial joint. The strength of manipulation is based on the patient's tolerance. Do not use too much force.

Intervention type: DRUG
Group type: OTHER
Intervention: Merislon
Description: Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks, 6mg a day, three times a day.
Study: NCT05662306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive and functional skills training
Description: Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
Study: NCT05880472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intratumoral
Description: Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
Study: NCT06148727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement
Description: Procedure/ surgery: Surgical placement of dental implants, four interforaminal dental implants were placed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement
Description: Procedure/ surgery: Surgical placement of dental implants, four interforaminal dental implants were placed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bar attachment
Description: Device: attachment, implants were connected to each others by 3 implant assembly in a trapezoidal design implants were loaded after 3 months of osseo-integration Control Group: patients received coventionally constructed heat cured overdenture Study Group: patients received 3d printed overdenture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bar attachment
Description: Device: attachment, implants were connected to each others by 3 implant assembly in a trapezoidal design implants were loaded after 3 months of osseo-integration Control Group: patients received coventionally constructed heat cured overdenture Study Group: patients received 3d printed overdenture
Study: NCT05384496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and/or Ipilimumab
Description: Combination of nivolumab 3mg/kg IV every 3 weeks with ipilimumab 1mg/kg or nivolumab 480mg IV every 4 weeks as monotherapy is considered standard of care for patients with unresectable locally advanced or metastatic mucosal melanoma.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT upon local or oligometastatic progression. The prescribed dose of SBRT will be 30 Gy in 5 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5mg twice daily
Study: NCT05702658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPS
Description: Community Autism Peer Support is a one-to-one autistic-delivered peer support, community-based intervention focused on independent living and participation.
Study: NCT06364982

Intervention type: DIAGNOSTIC_TEST
Intervention: Two contiguous dental implants placed with less ≤ 3mm from each other.
Description: Implant Placement of 2 contiguous dental implants with less ≤ 3mm from each other.

Intervention type: DIAGNOSTIC_TEST
Intervention: Two contiguous dental implants placed with > 3mm from each other.
Description: Implant Placement of 2 contiguous dental implants with \> 3mm from each other.
Study: NCT05381012

Intervention type: OTHER
Group type: OTHER
Intervention: Allodynia, quality of life, sleep, anxiety and depression, disability, and central sensitization
Description: All patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization.

Intervention type: OTHER
Group type: OTHER
Intervention: Allodynia, quality of life, sleep, anxiety and depression, disability, and central sensitization
Description: All patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization.

Intervention type: OTHER
Group type: OTHER
Intervention: Fibromyalgia syndrome
Description: Patients who meet the diagnostic criteria for fibromyalgia syndrome will be evaluated with the Fibromyalgia Impact Questionnaire.
Study: NCT04935125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Program + Endurance and Strength training
Description: Sessions of strength training added to a standard inpatient multidisciplinary programme

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Program + Endurance and Strength training
Description: Sessions of strength training added to a standard inpatient multidisciplinary programme

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Program
Description: Standard inpatient multidisciplinary programme (including endurance training)
Study: NCT06552806

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SLAB51
Description: One dose of SLAB51 is administered after arrival to high altitude, then three times a day approximately every 5 hours upon waking during Days 2 and 3, and a final dose the morning of Day 4 of acclimatization.
Study: NCT04861324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
Study: NCT05084612

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: standard LMA insertion
Description: Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete~the laryngeal mask will be inserted with using the standard method described by Brain; after lubrication of the posterior aspect of the partially deflated mask, the patient's head will be positioned with head extended at the atlanto-axial joint and flexed at the neck with non-dominant hand. The LMA will be held like a pen and index finger will be placed at the junction of LMA tube and cuff. Index finger will be used to press the LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of the hypopharynx. LMA will then be held with non-dominant hand and index finger will be removed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New technique LMA insertion
Description: Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete LMA will be inserted by a two Person Insertion with lateral rotation Technique; after lubrication of the posterior aspect of the partially deflated mask, the assistant will achieve jaw thrust and mouth opening then LMA will be inserted by the anaesthiologist. LMA will be inserted by holding the mask by index, middle finger and thumb; after insertion of the entire cuff inside the mouth, the LMA will be rotated anticlockwise through 90° (the inner surface of LMA will be directed medially towards the mouth cavity) and advanced through the side of the tongue until resistance felt, then turned back in the hypopharynx.
Study: NCT05249036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided arterial cannulation
Description: Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using real-time ultrasound guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation guided arterial cannulation
Description: Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using palpation technique (standard-of-care)
Study: NCT06281808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photon Counting Detector CT
Description: Photon counting detector CT scan with dose arbitrarily reduced compared to EID CT scan (e.g., half the dose of EID CT)
Study: NCT04075942

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Atrophic Anterior Maxillary Ridges
Description: Use of modified cortical shell technique grafted with customized Xenograft bone shell
Study: NCT05541848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferential current electro massage (ICE)
Description: Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
Study: NCT05126121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol
Description: Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
Study: NCT05090930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
Description: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
Description: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
Description: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
Description: HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
Description: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
Description: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
Description: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
Study: NCT05215093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct access physiotherapy for acute low back pain
Description: Interventions include physiotherapeutic treatment, without prescription of the general practitioner, for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
Study: NCT06552806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SLAB51
Description: One dose of SLAB51 is administered after arrival to high altitude, then three times a day approximately every 5 hours upon waking during Days 2 and 3, and a final dose the morning of Day 4 of acclimatization.
Study: NCT06282471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing and Problem-Solving Therapy (EW+PST)
Description: Participants will undergo a 6-week self-guided EW+PST. Participants will be provided with 6 printed journals (one for each week of the study) and instructed to write at least 2 entries per week.
Study: NCT05190237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCD21-55 group
Description: 2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
Study: NCT05090930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
Description: CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
Study: NCT05215093

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for acute low back pain
Description: Interventions include standard of care by the general practitioner for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
Study: NCT05190237

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TFD21-1 group
Description: 2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
Study: NCT05549869

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum leptin
Description: Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum leptin
Description: Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
Study: NCT05844956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Study: NCT05428800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: Progressive muscle relaxation (PMR) is a relaxation technique that tenses and relaxes muscles in an unprompted, regular, and consecutive manner until the whole body is relaxed.
Study: NCT06073860

Intervention type: DRUG
Intervention: Luspatercept
Description: According to the approved label
Study: NCT05332197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 17D Yellow fever vaccine
Description: This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. The exact potency of each batch is released with the certificate of analysis that accompanies each batch and the potency confirmed at time of release closest to internal minimum specification. This vaccine is the same vaccine used by the national EPI program
Study: NCT04758104

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium90
Description: Intracystic implantation of 90yttrium colloid
Study: NCT05296148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Implantation
Description: Implantation of a tricuspid coaptation valve through a transcatheter approach.
Study: NCT05434624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure.
Study: NCT05947747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXO-CD24
Description: Twice a day for 5 days, dose 10\^10

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day for 5 days